## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

## Equality impact assessment - Scoping

## STA Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

| 1.  | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-----|--|
| No  |  |
|     |  |
| 2.  | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?   |
| n/a |  |
|     |  |
| 3.  | Has any change to the draft scope been agreed to highlight potential equality issues?  |
| n/a |  |
|     |  |
| 4.  | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?  |
| No  |  |
|     |  |

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

Issue date: August 2020

| Approved by Associate Director (name): . | Ross Dent |
|--|-----------|
| Date: 28/07/20                           |           |

based chemotherapy Issue date: August 2020